Resistant mutations to alectinib in NSCLC are primarily in the I1171S/N residue mentioned above [185,189,190,191] which cause fluctuations in the A-loop and destabilize the drug ALK interaction [192]. This evidence concerns the gene ALK and non-small cell lung carcinoma.